Fusion

Fusion Pharmaceuticals Appoints New Chief Medical Officer

23rd March 2020

23 March 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of James J. O’Leary, M.D., as chief medical […]

Read More
Cancer Killers

Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. to its Board of Directors

6th February 2020

Boston, MA & Hamilton, February 6, 2020.   Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted alpha therapeutics, has announced the appointment of Pablo J. Cagnoni, M.D., to the board of directors. Dr. Cagnoni’s appointment as […]

Read More
Cancer Killers

Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board

13th January 2020

Hamilton, ON & Boston, MA – January 13, 2020 – Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board […]

Read More
Fusion

Fusion Raises $105m in Series B Financing

2nd April 2019

April 2nd 2019. Hamilton, Canada and Dublin, Ireland.  Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new […]

Read More
Fusion News

First Patient Dosed in Fusion Phase I trial

19th February 2019

Boston, Massachusetts & Hamilton, Ontario. February 19, 2019.  Seroba portfolio company, Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (targeted alpha therapeutics) has announced the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate […]

Read More
Fusion News

Seroba Invests in Fusion Pharmaceuticals

25th September 2017

Hamilton, Ontario, September 25, 2017. Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top